MedTrace Logo

Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection

NCT04750720 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2025-12-30

No results posted yet for this study

Summary

The main objective of the study is to describe the temporal curve of COVID-19 IgG and neutralizing antibodies over 24 months in an identified population of patients who presented with SARS-CoV-2 virus infection. The secondary objectives are to characterize the kinetics of the antibodies according to the severity of the clinical presentation and patient's characteristics and to determine if the anti-SARS-CoV-2 antibodies retain their neutralizing capacity over time. A sub-study aims to describe the kinetic of neutralizing antibodies (in blood and nasal mucosa) after vaccination.

Conditions

Interventions

OTHER

Sampling by venipuncture (and eventually by nasopharyngeal swab)

Biological samples : * Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test * PBMC (peripheral blood mononuclear cells) * Nasopharyngeal samples (not mandatory) Associated data : * Demographic data * Description of clinical manifestations related to SARS-CoV-2 infection * Notion of hospitalization/ambulatory follow-up Blood Fractioning * Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C) * Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells

Sponsors & Collaborators

  • Institut Pasteur

    collaborator INDUSTRY

  • Centre Hospitalier Régional d'Orléans

    lead OTHER

Principal Investigators

  • Thierry PRAZUCK, MD · CHU Orléans

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-27
Primary Completion
2022-03-07
Completion
2022-03-07

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750720 on ClinicalTrials.gov